MedTrace Logo

Efficacy and Safety of Empagliflozin in NODAT

NCT03642184 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-11-28

No results posted yet for this study

Summary

This is an open label, randomized controlled study. We'd like to access the safety and effects of empagliflozin compared with linagliptin in new-onset diabetes after kidney transplantation patients. Our primary endpoints are kidney related indicators and secondary endpoints are glucose and lipid metabolism related indicators and adverse events. We are going to recruit 35 patients for each group and follow six months.

Conditions

  • New Onset Diabetes After Transplant
  • Kidney Transplant; Complications

Interventions

DRUG

Empagliflozin

Dosage adjustment based on glucose targets . Once daily

DRUG

Linagliptin

Dosage adjustment based on glucose targets. Once daily

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Zhaohui Ni, Dr. · Renji Hospital, School of Medicine, Shanghai Jiao Tong University

  • Shan Mou, Dr. · Renji Hospital, School of Medicine, Shanghai Jiao Tong University

  • Yaomin Hu, Dr. · Renji Hospital, School of Medicine, Shanghai Jiao Tong University

  • Ming Zhang, Dr. · Renji Hospital, School of Medicine, Shanghai Jiao Tong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-14
Primary Completion
2019-01-31
Completion
2019-01-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03642184 on ClinicalTrials.gov